Date: 22 June 2010
Uwe Röhrhoff (48) succeeds Dr. Axel Herberg, who headed the business for ten years as CEO and is changing to the Supervisory Board on September 1, 2010.
“We are delighted to have found in Uwe Röhrhoff the ideal CEO for Gerresheimer AG,” says Supervisory Board Chairman Gerhard Schulze: “Mr. Röhrhoff stands for continuity and experience and enjoys the trust of customers and employees equally.”
Uwe Röhrhoff, a business graduate, works for Gerresheimer for 20 years and was recently responsible for the Moulded Glass Division and the Life Science Research Division. In addition, he has played a decisive role in the expansion of Gerresheimer’s US and Chinese business. Uwe Röhrhoff comments: “We will continue in the future to focus on the successful business in the field of pharma and healthcare. At the same time we want to push ahead with internationalization. We are very well positioned and solidly financed to achieve further profitable growth in the future.”
As CEO, Uwe Röhrhoff will continue to manage the Moulded Glass Division directly. On the Management Board, Dr. Max Raster takes over responsibility for the Life Science Research Division in addition to the Tubular Glass Division.
Uwe Röhrhoff joined Gerresheimer in 1991 and initially worked in controlling. He became CEO of the US subsidiary Gerresheimer Glass Inc. in 2001 and has many years’ experience of international business management.
Dr. Axel Herberg is leaving Gerresheimer under his own volition after his successful work as CEO. Dr. Herberg served the company for twenty years, fifteen of them as a member of the Management Board and ten as CEO. The Supervisory Board thanks him for his outstanding achievements and successful collaboration over the past years. It welcomes Dr. Axel Herberg as a new member of the Supervisory Board, to which he was elected by the Annual General Meeting on April 29, 2010 by a large majority of votes.
About Gerresheimer
Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma & healthcare industry. Our wide product spectrum ranges from pharmaceutical vials to complex drug delivery systems, such as syringe systems, insulin pens and inhalers, for safe dosage and application. Together with our partners we develop solutions which set standards and have role-model status throughout their respective business sectors.
Our Group of companies achieves in Europe, North and South America and Asia sales of about €1 billion and employs around 9,400 people. Through top-class technologies, convincing innovations and targeted investments we are systematically expanding our strong market position.
Add new comment